Clinical characteristics (New cases) | Conflict zone N = 21,131 (100%) | Non-conflict N = 43,826 (100%) | p-value |
PTB smear positive | 13,283 (63) | 14,016 (32) | < 0.001 |
PTB smear negative | 5309 (25) | 12,680 (30) | < 0.001 |
EPTB | 1963 (9) | 15,378 (35) | < 0.001 |
PTB (not done) | 576 (3) | 1392 (3) | 0.073 |
Treatment outcomes (New cases) | Conflict N = 20,326 n (%) | Non-conflict N = 43,826 n (%) | |
Treatment successa | 13,498 (66) | 28,645 (65) | < 0.001 |
Died | 422 (2) | 1124 (3) | < 0.001 |
Treatment failure | 139 (1) | 156 (< 1) | 0.703 |
LTFU | 1379 (7) | 4709 (10) | < 0.001 |
Transferred out | 592 (3) | 2141 (5) | 0.001 |
Not evaluated | 4296 (21) | 7051 (16) | 0.526 |
Clinical characteristics (Re-treatment cases) | Conflict zone N = 1822 (100%) | Non-conflict N = 2024 (100%) | |
After Relapse | 912 (50) | 1412 (70) | 0.005 |
After LTFUa | 669 (37) | 314 (16) | 0.014 |
After Failure | 155 (8) | 148 (7) | 0.804 |
Othersb | 86 (5) | 150 (7) | 0.276 |
Treatment outcomes (Re-treatment cases) | Conflict zone N = 1822 n (%) | Non-conflict N = 2024 n (%) | |
Treatment successa | 693 (38) | 911 (45) | < 0.001 |
Died | 146 (8) | 121 (6) | < 0.001 |
Treatment failure | 163 (9) | 122 (6) | < 0.001 |
LTFU | 218 (12) | 202 (10) | < 0.001 |
Transferred out | 200 (11) | 243 (12) | 0.986 |
Not evaluated | 402 (22) | 425 (21) | 0.713 |